Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.14, Zacks reports. During the same period in the prior year, the business earned ($0.50) earnings per share.
Lisata Therapeutics Price Performance
Shares of LSTA traded up $0.03 on Thursday, hitting $2.94. The company’s stock had a trading volume of 2,018 shares, compared to its average volume of 14,232. The company has a market capitalization of $24.42 million, a PE ratio of -1.17 and a beta of 1.24. Lisata Therapeutics has a fifty-two week low of $1.95 and a fifty-two week high of $3.83. The company has a 50 day moving average price of $3.36 and a 200 day moving average price of $3.09.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a research note on Tuesday.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
Further Reading
- Five stocks we like better than Lisata Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Walmart Stock: Buy the Rip or Wait for the Dip?
- Profitably Trade Stocks at 52-Week Highs
- 3 Stocks to Buy for a Soft Landing, If There Is One
- Business Services Stocks Investing
- Why You Shouldn’t Count Out Tencent Music Stock After Earnings
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.